Project Grant R21AI198948
- Federal Grant Award Summary Yale University received a $251,375 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 2, 2025, with a completion date of August 31, 2027. The grant supports research to identify new antigens in seronegative myasthenia gravis (SNMG), an autoimmune neuromuscular disorder characterized by the absence of detectable autoantibodies to known...
- Federal Grant Award Summary Yale University received a $819,674 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 15, 2026, with a completion date of April 30, 2031. The award supports the development of mechanistically informed deep learning computational models and experimental methodologies to identify autoreactive B cells in myasthenia gravis (MG), an...
- Federal Grant Award Summary Yale University received a $373,090 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 25, 2025, with a completion date of July 31, 2026. The award supports development of Modular Degraders of Extracellular Proteins (MODES), a novel therapeutic approach designed to remove pathogenic extracellular proteins from circulation. The research program...
- Federal Grant Award Summary Yale University received a $3.13 million Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 25, 2025, with a completion date of June 30, 2029. The grant funds investigator-initiated biomedical research focused on elucidating the mechanisms of lymphoid-specific beta-catenin protein degradation in B-lymphoid cells. The research will characterize how B-cells...
- Federal Project Grant Award Summary Yale University received a $105,402 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 27, 2026, with a completion date of April 15, 2029. The award supports investigator-initiated biomedical research focused on understanding the mechanisms of resilience to cytokinopathy flares in autoinflammatory diseases. The research addresses...
- Federal Grant Award Summary Yale University received a $735,631 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 1, 2026, with completion targeted for March 31, 2031. The research focuses on investigating the origin and functional properties of CX3CR1+ neutrophils, a novel neutrophil population with distinct biological characteristics compared to canonical neutrophils....
- Federal Grant Award Summary Yale University received a $662,465 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, with an ultimate completion date of January 31, 2031. This research initiative, titled "Durable and Broad Airway Immunity Through Next-Generation Intranasal Boosters," focuses on developing and understanding next-generation mucosal...
- Federal Project Grant Award Summary Yale University received a $778,828 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 6, 2026, with a completion date of March 31, 2031. This award supports investigator-initiated research examining novel loss-of-function gene variants in ZFYVE21 and their role in dysregulated innate immunity. The research deliverables include...
- Federal Project Grant Award Summary Yale University received a $405,585 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 18, 2025, with completion targeted for June 30, 2027. The grant supports the development of a multiplexed CRISPR activation and interference (CRISPRa/i) system designed to elucidate gene regulatory networks underlying T cell development in primary...
- Federal Grant Award Summary Yale University received a $4.9 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 14, 2025, with a completion date of June 30, 2029. The grant supports biomedical research investigating the mechanistic pathways by which gut microbiota and white adipose tissue control the CD4 T-cell compartment and facilitate T-cell migration from the...
Federal Grant Award Summary Yale University received a $251,938 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 9, 2026, with completion targeted for May 31, 2028. The grant supports investigator-initiated biomedical research focused on characterizing heterogeneity in autoimmune myasthenia gravis (MG) by identifying and analyzing disease variants driven by distinct immune mechanisms. The primary deliverables include molecular characterization of acetylcholine receptor (AChR)-specific immunoglobulin M (IgM) autoantibodies through generation of recombinant human monoclonal antibodies from patient B cell subsets, assessment of binding specificity and epitope targets, and definition of B cell phenotypes expressing these antibodies. Additionally, the project will deliver mechanistic investigation findings regarding IgM-driven pathology through cell-based assays evaluating complement activation, AChR blockade, and receptor internalization. The research aims to establish IgM-associated MG as a distinct clinical and immunological subset, moving beyond the traditional immunoglobulin G (IgG)-centric framework to explain treatment resistance in certain patient populations. Deliverables will include new diagnostic markers and therapeutic targets applicable to IgM-positive MG cases that do not respond to existing IgG-targeted therapies such as neonatal Fc receptor (FcRN) inhibitors. Work will be conducted at Yale University's New Haven, Connecticut facility.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $251.9k | 6/9/26 |